Resolution of Cullen’s sign in patient with metastatic melanoma responding to hypoxia-activated prodrug TH-302


Submitted: 27 October 2011
Accepted: 31 October 2011
Published: 1 December 2011
Abstract Views: 1711
PDF: 627
HTML: 652
Publisher's note
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.

Authors

  • Glen J. Weiss Virginia G. Piper Cancer Center Clinical Trials Program at Scottsdale Healthcare, Scottsdale, AZ, United States.
  • Karen Lewandowski Virginia G. Piper Cancer Center Clinical Trials Program at Scottsdale Healthcare, Scottsdale, AZ, United States.
  • Jon Oneall Virginia G. Piper Cancer Center Clinical Trials Program at Scottsdale Healthcare, Scottsdale, AZ, United States.
  • Stew Kroll Threshold Pharmaceuticals, Redwood City, CA, United States.
Cullen’s sign, ecchymosis of the subcutaneous periumbilical tissue often described in association with non-malignant conditions such as ruptured ectopic pregnancy or acute pancreatitis, has been reported in malignancies involving the abdomen. In melanoma, hematoma-like metastasis has been observed and can resolve with an effective therapy. We observed resolution of Cullen’s sign (probably hematoma-like metastasis) in a patient with metastatic melanoma. The patient was participating in a phase I clinical trial and treated with TH-302, a hypoxia-activated prodrug. After 2 months on study, complete resolution of Cullen’s sign resolved in concert with extracranial response in lung, liver, and lymph node metastases. Based on the dramatic extracranial response to this investigational agent, additional patients with metastatic melanoma without evidence of brain metastasis were treated on study with TH-302.

Supporting Agencies

Threshold Pharmaceuticals

Weiss, G. J., Lewandowski, K., Oneall, J., & Kroll, S. (2011). Resolution of Cullen’s sign in patient with metastatic melanoma responding to hypoxia-activated prodrug TH-302. Dermatology Reports, 3(3), e56. https://doi.org/10.4081/dr.2011.e56

Downloads

Download data is not yet available.

Citations